• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • S G Al Kindi G


    [9] S.G. Al-Kindi, G.H. Oliveira, Incidence and trends of cardiovascular mortality after common cancers in young adults: analysis of surveillance, epidemiology and end-results program, World J. Cardiol. 8 (2016) 368–374.
    [19] J. Moslehi, A.K. Pandey, N. Bhatia, Cardio-oncology: vascular endothelial growth
    [27] M. Guberina, W. Eberhardt, M. Stuschke, T. Gauler, F. Heinzelmann, D. Cheufou, et al., Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial, Ann. Oncol. 28 (2017) 1084–1089.
    [37] M.L. Bots, A. Hofman, D.E. Grobbee, Increased common carotid intima-media thick-ness. Adaptive response or a reflection of atherosclerosis? Findings from the Rot-terdam Study, Stroke 28 (1997) 2442–2447.
    [42] G. Minotti, R. Ronchi, E. Salvatorelli, P. Menna, G. Cairo, Doxorubicin irreversibly in-activates iron regulatory 6-NBDG 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitu-mor therapy, Cancer Res. 61 (2001) 8422–8428.
    [48] G. Heusch, J. Rose, A. Skyschally, H. Post, R. Schulz, Calcium responsiveness in re-gional myocardial short-term hibernation and stunning in the in situ porcine heart. Inotropic responses to postextrasystolic potentiation and intracoronary cal-cium, Circulation 93 (1996) 1556–1566.
    [49] P. Gajalakshmi, M.K. Priya, T. Pradeep, J. Behera, K. Muthumani, S. Madhuwanti, et al., Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endothelium, Toxicol. Appl. Pharmacol. 269 (2013) 121–131.
    [65] P.S. Hall, L.C. Harshman, S. Srinivas, R.M. Witteles, The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma pa-tients, JACC Heart Fail. 1 (2013) 72–78.
    [68] M. Totzeck, R.I. Mincu, T. Rassaf, Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients, J. Am. Heart Assoc. 6 (2017).
    [79] R. Gibson, J. Delaune, A. Szady, M. Markham, Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer, BMJ Case Rep. 2016 (2016). [80] T. Okazaki, Y. Tanaka, R. Nishio, T. Mitsuiye, A. Mizoguchi, J. Wang, et al., Autoanti-bodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice, Nat. Med. 9 (2003) 1477–1483.
    [84] P. Thavendiranathan, F. Poulin, K.D. Lim, J.C. Plana, A. Woo, T.H. Marwick, Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic re-view, J. Am. Coll. Cardiol. 63 (2014) 2751–2768.
    [85] I.A. Paraskevaidis, G. Makavos, P. Tsirigotis, P. Psarogiannakopoulos, J. Parissis, K. Gkirkas, et al., Deformation analysis of myocardial layers detects early cardiac dys-function after chemotherapy in bone marrow transplantation patients: a continu-ous and additive cardiotoxicity process, J. Am. Soc. Echocardiogr. 30 (2017) 1091–1102.
    [86] H.K. Narayan, B. Finkelman, B. French, T. Plappert, D. Hyman, A.M. Smith, et al., De-tailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of fol-low-up, Circulation 135 (2017) 1397–1412.
    [87] S.M. Davidson, S. Arjun, M.V. Basalay, R.M. Bell, D.I. Bromage, H.E. Botker, et al., The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection-evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology, Basic Res. Cardiol. 113 (2018) 43.
    [92] G.C. Connolly, L. Menapace, S. Safadjou, C.W. Francis, A.A. Khorana, Prevalence and clinical significance of incidental and clinically suspected venous thromboembo-lism in lung cancer patients, Clin. Lung Cancer 14 (2013) 713–718.
    [95] C.M. Tully, A.B. Apolo, E.C. Zabor, A.M. Regazzi, I. Ostrovnaya, H.F. Furberg, et al., The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents, Cancer 122 (2016) 712–721.
    [99] F. Khosrow-Khavar, K.B. Filion, S. Al-Qurashi, N. Torabi, N. Bouganim, S. Suissa, et al., Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials, Ann. Oncol. 28 (2017) 487–496.
    [100] J.D. Groarke, P.L. Nguyen, A. Nohria, R. Ferrari, S. Cheng, J. Moslehi, Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease, Eur. Heart J. 35 (2014) 612–623.
    [107] P. Ponikowski, A.A. Voors, S.D. Anker, H. Bueno, J.G. Cleland, A.J. Coats, et al., 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur. Heart J. 37 (2016) 2129–2200.